 | Up a level |
Peyvandi, F; Scully, M; Kremer Hovinga, Johanna Anna; Knöbl, P; Cataland, S; De Beuf, K; Callewaert, F; De Winter, H; Zeldin, R K (2017). Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 15(7), pp. 1448-1452. Wiley-Blackwell 10.1111/jth.13716
Scully, M; Cataland, S; Coppo, P; de la Rubia, J; Friedman, K D; Kremer Hovinga, Johanna Anna; Lämmle, Bernhard; Matsumoto, M; Pavenski, K; Sadler, E; Sarode, R; Wu, H (2017). Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of thrombosis and haemostasis, 15(2), pp. 312-322. Wiley-Blackwell 10.1111/jth.13571
